Peptide (e.g., Protein, Etc.) Containing Doai Patents (Class 514/1.1)
  • Patent number: 11559612
    Abstract: The invention relates to self-assembled organosilane- and small molecule drug-containing coatings for resorbable medical implant devices. The coatings can be prepared from precursor compositions containing an organosilane and a small molecule drug, and can be applied to substrates. Prior to applying the coatings, the surfaces of the substrates can be pretreated. The coatings can be functionalized with a binding compound that is coupled with an active component. The coatings can be applied using various techniques and apparatus, more particularly, by a deep-coating process conducted at ambient conditions.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: January 24, 2023
    Assignee: UNIVERSITY OF PITTSBURGH —OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION
    Inventors: Elia Beniash, Avinash Patil
  • Patent number: 11535663
    Abstract: The present disclosure pertains to compositions comprising anti-VEGF proteins and methods for producing such compositions.
    Type: Grant
    Filed: July 22, 2021
    Date of Patent: December 27, 2022
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Shawn Lawrence, Amy Johnson, Meghan Casey, Jaimie Mastrogiacomo, Shunhai Wang, Ning Li
  • Patent number: 11529390
    Abstract: The present invention relates to PCSK9 inhibitors and methods of use thereof. Specifically, the invention relates to PCSK9 cell-based assay, PCSK9 inhibiting polypeptides and derivatives thereof. The invention includes pharmaceutical compositions comprising a PCSK9 inhibitor polypeptide together with a pharmaceutically acceptable carrier and method for treating cardiovascular disorders, hyperlipidemia, inflammatory diseases or inflammatory response to infection.
    Type: Grant
    Filed: November 12, 2020
    Date of Patent: December 20, 2022
    Assignee: INSTITUT DE CARDIOLOGIE DE MONTREAL
    Inventors: Steve Poirier, Gaetan Mayer
  • Patent number: 11524050
    Abstract: Polypeptides comprising a C3b binding region are disclosed, as well as nucleic acids and vectors encoding such polypeptides, and cells and compositions comprising such polypeptides. Also disclosed are uses and methods using the polypeptides for treating and preventing diseases and conditions.
    Type: Grant
    Filed: January 15, 2019
    Date of Patent: December 13, 2022
    Assignee: Complement Therapeutics Limited
    Inventors: Paul Bishop, Simon Clark, Richard Unwin
  • Patent number: 11510988
    Abstract: The present invention is directed to carrier systems comprising ether-lipids conjugated to one or more bioactive ligands and exposed on the surface of the carrier system for use in targeted delivery and/or antigen display systems. Optionally one or more further bioactive agents may be encapsulated or embedded within or attached to or adsorbed onto the carrier system. The present invention is further directed to methods of their preparation and their uses in medical applications, such as targeted delivery of bioactive agents to specific tissues or cells and antigen display systems for the study, diagnosis, and treatment of traits, diseases and conditions that respond to said bioactive agents.
    Type: Grant
    Filed: January 11, 2018
    Date of Patent: November 29, 2022
    Assignee: Merck Patent GmbH
    Inventors: Michael Platscher, Raymond Behrendt, Viola Groehn, Simone Hoertner, Marco Passafaro, Finn Bauer
  • Patent number: 11484505
    Abstract: This invention provides compositions comprising at least one protein nanoparticle comprising a protein and a stealth polymer. In certain embodiments, the nanoparticle further comprises a therapeutic agent, such as but not limited to a miRNA and/or siRNA. In other embodiments, the nanoparticle further comprises a cell surface receptor ligand. Also included in the invention are methods of preparing the compositions of the present invention, and methods of treating, ameliorating or preventing a disease or disorder in a subject using the compositions of the present invention.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: November 1, 2022
    Assignee: Thomas Jefferson University
    Inventor: Sunday Shoyele
  • Patent number: 11478534
    Abstract: This invention is directed to a zinc-charged insulin composition that is effective in treating diabetes and lowering and stabilizing blood glucose levels when administered orally. The zinc-charged insulin is acid and enzyme resistant, such that the zinc-charged insulin is capable of surviving the acidic conditions of the stomach. The zinc-charged insulin is capable of being absorbed through the gastrointestinal tract and stored in the liver, such that the zinc-charged insulin is long lasting and pharmacokinetically similar to the insulin normally generated by the body. The invention is further directed to a method of preparing the zinc-charged insulin composition, including: (1) removing any loosely bound surface ions present on an insulin molecule using a chelating agent; and (2) replacing all the loosely bound surface ions with zinc.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: October 25, 2022
    Inventor: Men Hwei Tsai
  • Patent number: 11479773
    Abstract: The present invention provides an antisense oligonucleotide for inhibiting biosynthesis of chondroitin sulfate. The antisense oligonucleotide comprises at least one modified nucleotide, wherein the antisense oligonucleotide suppresses expression of one or both of the chondroitin sulfate N-acetylgalactosaminyltransferase-1 (CSGalNAcT1) gene and the chondroitin sulfate N-acetylgalactosaminyltransferase-2 (CSGalNAcT2) gene.
    Type: Grant
    Filed: February 20, 2018
    Date of Patent: October 25, 2022
    Assignees: Aichi Medical University, National Institutes of Biomedical Innovation, Health and Nutrition
    Inventors: Satoshi Obika, Yuya Kasahara, Kosei Takeuchi
  • Patent number: 11458107
    Abstract: The present invention relates generally to compositions and methods comprising abiotic, synthetic polymers with affinity and specificity to proteins. The synthetic polymers are an improvement over biological agents by providing a simpler, less expensive, and customizable platform for binding to proteins. In one embodiment, the compositions and methods relate to synthetic polymers with affinity and specificity to vascular endothelial growth factor (VEGF). In one embodiment, the compositions are useful for treating diseases and disorders related to the overexpression of VEGF. In one embodiment, the compositions are useful for treating cancer. In one embodiment, the compositions are useful for detecting VEGF levels from biological samples. In one embodiment, the compositions are useful for detecting overexpression of VEGF from biological samples. In one embodiment, the compositions are used to diagnose cancer.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: October 4, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Kenneth J. Shea, Hiroyuki Koide, Yoshiko Miura, Yu Hoshino, Yuri Nishimura, Naoto Oku
  • Patent number: 11453725
    Abstract: The invention provides methods for selective targeting of live cells, which have undergone or are undergoing radiation or chemotherapy, at a site of interest with a cell-penetrating polypeptide. In one embodiment of the invention, the method comprises contacting the live cells with a cell-penetrating polypeptide comprising cell-penetrating determinants so that the cell-penetrating polypeptide binds extracellular DNA near or around the live cells so as to form a complex or association therewith such that the complex or associated polypeptide-DNA so bound bind the live cells and penetrates the live cells thereby selectively targeting live cells at a site of interest with a cell-penetrating polypeptide.
    Type: Grant
    Filed: August 19, 2019
    Date of Patent: September 27, 2022
    Assignee: THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Richard H. Weisbart, Robert N. Nishimura
  • Patent number: 11446398
    Abstract: The present invention provides regulatable biocircuit systems. Such systems provide modular and tunable protein expression systems in support of the discovery and development of therapeutic modalities.
    Type: Grant
    Filed: April 11, 2017
    Date of Patent: September 20, 2022
    Assignee: OBSIDIAN THERAPEUTICS, INC.
    Inventors: Peter Barrett, Michael N. Gladstone, Tariq A. Kassum, Vipin Suri, Dan Jun Li, Dexue Sun, Brian Dolinski
  • Patent number: 11427617
    Abstract: Novel peptide analogs of a ?-defensin have been developed that provide a biphasic effect in treating disseminated fungal disease and/or associated septic shock. These analogs are active at concentrations below those needed to provide a fungicidal effect, and function by initially mobilizing effector cells of the immune system to address the infective organism followed by regulation of the immune system to down regulate the inflammatory response. These novel ?-defensin analogs are protective at concentrations where naturally occurring ?-defensins have no apparent effect, and include a core set of structural and sequence features not found in native ?-defensins.
    Type: Grant
    Filed: June 26, 2020
    Date of Patent: August 30, 2022
    Assignee: THE UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Michael E. Selsted, Dat Q. Tran, Justin B. Schaal, Virginia Basso
  • Patent number: 11423041
    Abstract: History for data objects may be maintained to detect data events. An indication of an Extract, Transform, Load (ETL) process applied to one or more source data objects to generate one or more transformed data objects may be received. History for the source data objects may be updated to include the transformed data objects and the ETL process that generated the transformed data objects. An evaluation of the update may be performed to determine whether an event associated with the data lineage is triggered. If the event is triggered, a notification of the event may be sent to one or more subscribers for the event.
    Type: Grant
    Filed: January 24, 2020
    Date of Patent: August 23, 2022
    Assignee: Amazon Technologies, Inc.
    Inventors: George Steven McPherson, Mehul A. Shah, Prajakta Datta Damle, Gopinath Duddi, Anurag Windlass Gupta
  • Patent number: 11420998
    Abstract: The present disclosure provides methods of preventing or treating renal ischemia-reperfusion injury in a mammalian subject and methods for chronic treatment of ARVD, including administering an effective amount of an aromatic-cationic peptide to a subject in need thereof. The methods include administering aromatic-cationic peptides to prevent or treat renal injury during the treatment of renal artery stenosis. The methods include administering an effective amount of an aromatic-cationic peptide to subjects in need thereof.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: August 23, 2022
    Assignees: Stealth Biotherapeutics Inc., Mayo Foundation for Medical Education and Research
    Inventors: D. Travis Wilson, Lilach O. Lerman, Stephen C. Textor
  • Patent number: 11413323
    Abstract: The invention provides ophthalmic compositions comprising about 0.1 % (w/v) cyclosporine dissolved in 1-(perfluorobutyl)pentane for use in the topical treatment of dry eye disease. The invention further provides kits comprising such compositions for the same use.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: August 16, 2022
    Assignee: NOVALIQ GMBH
    Inventors: Chiara Silvana Leo, Sonja Krösser, Thomas Schlüter, Alice Meides
  • Patent number: 11413308
    Abstract: Methods and compositions for treating and/or preventing aging-related conditions are described. The compositions used in the methods include blood plasma and blood plasma fractions derived from blood plasma with efficacy in treating and/or preventing aging-related conditions such as cognitive disorders. The methods relate to a regimen of pulsed dosing of blood plasma or blood plasma fractions.
    Type: Grant
    Filed: November 13, 2020
    Date of Patent: August 16, 2022
    Assignee: Alkahest, Inc.
    Inventors: Steven P. Braithwaite, Eva Czirr, Ian Gallager, Nina Huber, S. Sakura Minami
  • Patent number: 11407811
    Abstract: The invention discloses a fusion protein, preparation method thereof and use thereof and belongs to the field of biopharmaceutical technology. The fusion protein according to the present invention has anti-tumor, anti-autoimmune diseases and anti-inflammatory functions, and therapeutic effects on ophthalmic diseases. According to the long-acting, multifunctional fusion protein of the present invention, the EDSM-Y or EDSM-X polypeptide is fused to the antibody immunoglobulin Fc fragment by a flexible linker so as to obtain the fusion proteins I-V, which can improve the efficacy, prolong the half-life and enhance stability, have characteristics of strong effect, low toxicity and the like, and can be used for the prevention and treatment of solid tumors and various types of inflammation and neovascular ophthalmic diseases. The fusion protein is expressed in a prokaryotic cell or a eukaryotic cell by a genetic engineering method, and the expressed fusion protein is obtained by affinity chromatography.
    Type: Grant
    Filed: March 5, 2018
    Date of Patent: August 9, 2022
    Assignee: JIANGSU RONGTAI BIOTECH CO., LTD.
    Inventor: Hanmei Xu
  • Patent number: 11408892
    Abstract: Methods, systems and computer-accessible medium for imaging a living cell or a living organism with bond-edited compounds using stimulated Raman scattering are disclosed. The method comprises the steps of introducing one or more bond-edited compounds into a live cell or a living organism, and detecting a vibrational tag in the cell or organism with stimulated Raman scattering. Also disclosed are methods for detecting a disease condition in a subject, methods for monitoring treatment for a disease condition, methods for screening an agent, methods for tracing a cellular process in a live cell using bond-edited compounds in combination with stimulated Raman scattering. Also disclosed are a composition for labeling a target cell with at least one bond-edited compound and devices for imaging bond-edited compounds by stimulated Raman scattering.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: August 9, 2022
    Assignee: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
    Inventors: Wei Min, Lu Wei, Zhixing Chen, Fanghao Hu, Yihui Shen
  • Patent number: 11401380
    Abstract: Polyethylene glycol (PEG)-b-poly(?-amino ester) (PBAE) co-polymers (PEG-PBAE) and blends of PEG-PBAEs and PBAEs and their use for delivering drugs, genes, and other pharmaceutical or therapeutic agents safely and effectively to different sites in the body and to different cells, such as cancer cells, are disclosed.
    Type: Grant
    Filed: March 28, 2016
    Date of Patent: August 2, 2022
    Assignee: THE JOHNS HOPKINS UNIVERSITY
    Inventors: Jordan Green, Jayoung Kim, Stephany Tzeng
  • Patent number: 11400188
    Abstract: The present specification discloses plasma processing systems that include a number of different fluid flow circuits that are defined by sources of fluid, fluid lines, fluid flow paths, waste containers, a mixer, a separator, valves, and a pump. The systems also include a connector tube and a solvent extraction device, wherein the connector tube and solvent extraction device are configured to be alternatively inserted in a same position along a fluid flow line. In addition, the systems include a controller that is configured to execute a plurality of programmatic instructions to open and close each of a first fluid flow line valve, a second fluid flow line valve, a third fluid flow line valve, and a fourth fluid flow line valve in a predetermined sequence to either enable or prevent a flow of fluid through various fluid flow lines.
    Type: Grant
    Filed: September 4, 2020
    Date of Patent: August 2, 2022
    Assignee: HDL Therapeutics, Inc.
    Inventors: Hollis Bryan Brewer, Jr., Michael M. Matin, Timothy Jon Perlman
  • Patent number: 11395862
    Abstract: A bone cement paste containing a powder component comprising ?-tricalcium phosphate (?-TCP) particles having an average size greater than or equal to 9 ?m, and a liquid component comprising blood is disclosed. A method for preparation of the phosphocalcic cement composition is also disclosed.
    Type: Grant
    Filed: April 6, 2017
    Date of Patent: July 26, 2022
    Assignees: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, UNIVERSITE DE NANTES, ONIRIS, GRAFTYS
    Inventors: Jean-Michel Bouler, Olivier Gauthier, Bruno Bujoli, Pascal Janvier, Charlotte Mellier
  • Patent number: 11389392
    Abstract: The present invention relates generally to methods of use and compositions useful for treating skin. The composition includes a combination of Argania spinosa kernel extract, dill extract, Myrciaria dubia fruit extract, and Croton lechleri extract and/or Morus alba fruit extract. This combination can be used to create topical skin compositions that reduce the appearance of loose, sagging, and/or flaccid skin, and/or improve facial contouring.
    Type: Grant
    Filed: June 13, 2018
    Date of Patent: July 19, 2022
    Assignee: MARY KAY INC.
    Inventors: Geetha Kalahasti, Michelle Hines, David Gan, Tiffany Carle
  • Patent number: 11390655
    Abstract: The disclosure provides a chimeric antigen receptor (CAR) comprising a modified hinge, transmembrane and/or intracellular domain disclosed herein. Some aspects of the disclosure relate to a polynucleotide encoding a chimeric antigen receptor (CAR) comprising the costimulatory domain disclosed herein. Other aspects of the disclosure relate to cells comprising the CAR and use in a T cell therapy.
    Type: Grant
    Filed: November 15, 2018
    Date of Patent: July 19, 2022
    Assignee: Kite Pharma, Inc.
    Inventors: Stuart A. Sievers, Jed J. W. Wiltzius
  • Patent number: 11382871
    Abstract: The subject matter of the invention is a pharmaceutical formulation which, according to the invention, contains curcumin or a curcumin derivative dissolved in an alcohol, an acid and an solubiliser. The formulation contains at most 12 percent by weight water and makes possible the production of an aqueous infusion solution, by means of which curcumin can be administered intravenously in dissolved form.
    Type: Grant
    Filed: July 24, 2013
    Date of Patent: July 12, 2022
    Assignee: BRIU GMBH
    Inventor: Uwe-Bernd Rose
  • Patent number: 11369683
    Abstract: The present invention relates to nanoparticles. In particular, the present invention provides nanoparticles for clinical (e.g., targeted therapeutic), diagnostic (e.g., imaging), and research applications in the field of cardiology. For example, in some embodiments, the present invention provides a method of treating (e.g., ablating) cardiac tissue, comprising: a) contacting an animal with a nanoparticle comprising a matrix, a toxic (e.g., ablative) agent (e.g., sonosensitizer, chemotherapeutic agent (e.g., doxorubicin or cisplatin), or photosensitizer), and a cardiac targeting moiety; and b) administering an activator of the toxic agent (e.g., light, chemical (e.g., pharmaceutical agent) or ultrasound) to at least a portion of the cardiac tissue (e.g., heart) of the animal to activate the toxic agent.
    Type: Grant
    Filed: December 10, 2019
    Date of Patent: June 28, 2022
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Jerome Kalifa, Raoul Kopelman, Uma Mahesh R. Avula, Gwangseong Kim, Yong-Eun Koo Lee, Hyung Ki Yoon
  • Patent number: 11365228
    Abstract: The present invention relates, in one aspect, to certain mutant FGF21 polypeptide constructs. In certain non-limiting embodiments, the construct binds to ?-Klotho more tightly than wild-type FGF21. In certain non-limiting embodiments, the construct has a mutation in at least one residue of SEQ ID NO:3 selected from the group consisting of V188, R203, and L194. In certain non-limiting embodiments, the construct further comprises a stability enhancing domain.
    Type: Grant
    Filed: July 5, 2018
    Date of Patent: June 21, 2022
    Assignee: YALE UNIVERSITY
    Inventors: Joseph Schlessinger, Sangwon Lee
  • Patent number: 11365218
    Abstract: Disclosed are a bifunctional peptide having the capability to reduce inflammation and the capability to facilitate differentiation of stem cells into chondrocytes and the use thereof. Advantageously, the bifunctional peptide is useful for the prevention or treatment of arthritis accompanied by inflammation and damage of cartilage tissue due to excellent effects of reducing inflammation and facilitating differentiation of stem cells into chondrocytes, can be easily applied to various surgical regenerative treatments including orthopedic treatments, and can shorten the treatment period.
    Type: Grant
    Filed: May 25, 2020
    Date of Patent: June 21, 2022
    Assignees: SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION, NANO INTELLIGENT BIOMEDICAL ENGINEERING CORPORATION CO. LTD.
    Inventors: Yoon Jeong Park, Chong-Pyoung Chung, Jue-Yeon Lee
  • Patent number: 11364277
    Abstract: A method for treating ascites patients by administering the peptide drug terlipressin by continuous infusion. The patients include those whose ascites condition has not progressed to hepatorenal syndrome (HRS). Administration may be accomplished with a continuous infusion pump.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: June 21, 2022
    Assignee: BioVie Inc.
    Inventors: Paolo Angeli, Penelope Markham, Jonathan Adams
  • Patent number: 11364304
    Abstract: Methods of preparing crosslinked spherical nucleic acids (SNAs) using thermoresponsive traceless templates, such as PEO-PPO-PEO block copolymers. The crosslinks can be added between oligonucleotides within the same SNA or oligonucleotides between multiple different SNAs.
    Type: Grant
    Filed: August 25, 2017
    Date of Patent: June 21, 2022
    Assignee: Northwestern University
    Inventors: Chad A. Mirkin, SonBinh T. Nguyen, Resham J. Banga
  • Patent number: 11359186
    Abstract: The present invention provides an artificial nuclease comprising a DNA-binding domain and a function domain linked to each other via a polypeptide consisting of 35 to 55 amino acid residues wherein amino acid residues at two sites in a DNA-binding module contained in a DNA-binding domain exhibit a mode of repetition that is different for every four DNA-binding modules; a vector for expressing said artificial nuclease; a vector library for preparing said vector; and a vector set for preparing said vector library.
    Type: Grant
    Filed: June 6, 2018
    Date of Patent: June 14, 2022
    Assignee: Hiroshima University
    Inventors: Takashi Yamamoto, Tetsushi Sakuma, Hiroshi Ochiai, Shinya Matsuura, Tatsuo Miyamoto
  • Patent number: 11360077
    Abstract: Disclosed are methods and compositions for identifying and treating certain conditions and diseases. In certain instances, the general inventive concepts provide methods for determining rhTRAIL sensitivity of a sample and/or methods and compositions for inducing apoptosis to treat conditions and diseases with rhTRAIL.
    Type: Grant
    Filed: March 12, 2018
    Date of Patent: June 14, 2022
    Assignee: Cleveland State University
    Inventors: Michael Kalafatis, Katherine Turner
  • Patent number: 11352400
    Abstract: Fusion peptide comprising: i) an amino acid sequence as defined in SEQ ID No.: 1 or a related homolog having at least 90% identity with SEQ ID No.: 1 and having the ability of the sequence SEQ ID No.: 1 to inhibit the kinase-independent function of PI3K?, and ii) a peptide having the ability to penetrate a cell.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: June 7, 2022
    Assignee: KITHER BIOTECH SRL
    Inventors: Emilio Hirsch, Alessandra Ghigo
  • Patent number: 11337994
    Abstract: Described herein are in situ gelling compositions. The compositions include an anti-inflammatory polysaccharide and a gelling polymer, wherein the composition is a liquid prior to administration to a subject but converts to a gel upon administration to the subject. The compositions described herein have numerous applications with respect to the local treatment (reduction or prevention) of inflammation and/or tissue damage.
    Type: Grant
    Filed: September 14, 2017
    Date of Patent: May 24, 2022
    Assignee: UNIVERSITY OF UTAH RESEARCH FOUNDATION
    Inventors: Hamidreza Ghandehari, Siam Oottamasathien, Mark Martin Jensen, Joseph Cappello, Wanjian Jia, Glenn D. Prestwich
  • Patent number: 11331366
    Abstract: The present invention provides a composition for suppressing muscular atrophy, comprising as an active ingredient(s) one or more peptides selected from the group consisting of tripeptides DIY, IYN, YNP, NPQ, DFY, DIF, FYN, IFN, FNP, and NPK; the group consisting of dipeptides comprising F; and the group consisting of dipeptides DI, IY, YN, and NP.
    Type: Grant
    Filed: December 4, 2017
    Date of Patent: May 17, 2022
    Assignee: OTSUKA PHARMACEUTICAL CO., LTD.
    Inventors: Muneshige Shimizu, Akina Shiokawa, Koichiro Hamada, Kiyohiko Magata, Takeshi Nikawa, Ayako Maita
  • Patent number: 11325951
    Abstract: This disclosure is directed to immune treatment of a disease (e.g., cancer) using a fusion protein in combination with an anti-chemorepellant agent. In particular, the fusion protein comprises an antigen-binding domain (e.g., an antibody or antibody fragment) and a stress protein domain.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: May 10, 2022
    Assignee: The General Hospital Corporation
    Inventors: Mark C. Poznansky, Jeffrey A. Gelfand
  • Patent number: 11324806
    Abstract: A method of treating a bone defect is provided. The method comprises administering to the bone defect an amount of about 0.1 ?g to about 800 ?g of growth differentiation factor 5 (GDF-5) over a period of at least three days. An implantable matrix for treating a bone defect is also provided.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: May 10, 2022
    Assignee: Warsaw Orthopedic, Inc.
    Inventor: Ping Li
  • Patent number: 11304975
    Abstract: The present invention relates to methods for developing engineered T-cells for immunotherapy that are non-alloreactive. The present invention relates to methods for modifying T-cells by inactivating both genes encoding T-cell receptor and an immune checkpoint gene to unleash the potential of the immune response. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
    Type: Grant
    Filed: May 13, 2014
    Date of Patent: April 19, 2022
    Assignee: CELLECTIS
    Inventors: Roman Galetto, Agnes Gouble, Stephanie Grosse, Cécile Schiffer-Mannioui, Laurent Poirot, Andrew Scharenberg, Julianne Smith
  • Patent number: 11306329
    Abstract: Provided herein are adeno-associated virus (AAV) compositions that can restore F8 gene function in a cell without co-transducing or co-administering an exogenous nuclease or a nucleotide sequence that encodes an exogenous nuclease. Also provided are methods of using the AAV compositions to correct an F8 gene mutation and/or treat a disease or disorder associated with an F8 gene mutation. Packaging systems for making the adeno-associated virus compositions are also provided.
    Type: Grant
    Filed: February 19, 2019
    Date of Patent: April 19, 2022
    Assignees: CITY OF HOPE, HOMOLOGY MEDICINES, INC.
    Inventors: Saswati Chatterjee, Laura Jane Smith, Jeff Lynn Ellsworth, Hillard Rubin, Jason Boke Wright, James Anthony McSwiggen
  • Patent number: 11305011
    Abstract: The present invention provides compositions and methods for treating KMA-expressing malignancies including chimeric antigen receptors (CARs) and T cells containing CARs (CAR T-cells). The invention also provides methods and compositions comprising CAR T-cells co-expressing other anti-tumoral agents including cytokines and antibodies.
    Type: Grant
    Filed: April 25, 2016
    Date of Patent: April 19, 2022
    Assignee: HAEMALOGIX PTY. LTD.
    Inventors: Kenneth Micklethwaite, Rosanne Dunn, David Gottlieb, Grant Logan
  • Patent number: 11298391
    Abstract: In various implementations, a skin therapeutic may be topically applied to improve skin health. The skin therapeutic may decrease inflammation, decrease redness, and/or decrease health times. The skin therapeutic may include a composition that includes two or more of Brassica olearacea italica Seed Oil, bisabolol, and/or Zingiber officinales.
    Type: Grant
    Filed: April 27, 2018
    Date of Patent: April 12, 2022
    Assignee: Lorenol Laboratories, Inc.
    Inventor: Laura Montry
  • Patent number: 11273197
    Abstract: Provided herein are compositions and methods for treating dry eye or an ocular disease associated with inflammation in a subject in need thereof. The therapeutic compositions comprise an adiponectin peptidomimetic compound, and a pharmaceutically acceptable carrier, and administering a therapeutic agent. Also provided are methods for alleviating one or more symptoms or clinical signs of dry eye or an ocular disease associated with inflammation in a subject in need thereof.
    Type: Grant
    Filed: November 24, 2019
    Date of Patent: March 15, 2022
    Assignee: ALLYSTA PHARMACEUTICALS, INC.
    Inventor: Henry Hsu
  • Patent number: 11273130
    Abstract: The present disclosure provides a method for delivering a neuroprotective polypeptide to at least a portion of a central nervous system (CNS) of a subject.
    Type: Grant
    Filed: October 20, 2017
    Date of Patent: March 15, 2022
    Assignees: The United States, as represented by the Secretary Department of Health and Human Services, Peptron, Inc.
    Inventors: Dong Seok Kim, Hee Kyung Kim, Nigel H. Greig
  • Patent number: 11274158
    Abstract: The present invention provides methods for treating inflammatory or autoimmune disease using calcitonin receptor activators, such as calcitonin receptor activating antibodies, among others. The invention also features compositions containing calcitonin receptor activators, methods of diagnosing patients with calcitonin receptor-associated inflammatory or autoimmune disease, and methods of predicting the response of an inflammatory or autoimmune disease or condition in a subject to treatment with calcitonin receptor activators.
    Type: Grant
    Filed: September 24, 2018
    Date of Patent: March 15, 2022
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Avak Kahvejian, Jordi Mata-Fink, Jonathan Barry Hurov, Chengyi Jenny Shu, George Huck Neubauer, Manuel Andreas Fankhauser, Julian Alexander Stanley
  • Patent number: 11266675
    Abstract: There are disclosed methods of treatment of viral infection. The method makes use of administration of an anti-Hsc70 inhibitor. There are also disclosed uses of anti-Hsc70 inhibitor.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: March 8, 2022
    Assignee: CITY UNIVERSITY OF HONG KONG
    Inventor: Ming-liang He
  • Patent number: 11266762
    Abstract: Methods for producing a fibrin matrix comprising a fusion peptide are described herein. In some embodiments, the method includes providing three different components, including a first component containing fibrinogen or a fibrinogen precursor and optionally, transglutaminase or a transglutaminase precursor, a second component containing thrombin or a thrombin precursor, and a third component containing a fusion peptide. In these embodiments, neither the first component nor the second component includes the fusion peptide. In some embodiments, the first or second components are premixed with the third component. The first, second and third components are mixed to form a fibrin matrix comprising a covalently linked fusion peptide. The mixing is carried out in a time frame of not more than 5 days. A kit for producing the fibrin matrix comprising a covalently linked fusion peptide is also described herein.
    Type: Grant
    Filed: March 6, 2019
    Date of Patent: March 8, 2022
    Assignee: KUROS BIOSURGERY AG
    Inventors: Lorenz Vogt, Alistair Simpson Irvine, Philippe Paul Saudan
  • Patent number: 11260107
    Abstract: The present disclosure provides compositions and methods for treating or preventing ulcers in subjects having low red blood cell levels and/or hemoglobin levels (e.g, anemia). In some embodiments, the compositions of the disclosure may be used to treat or prevent ulcers associated with anemia.
    Type: Grant
    Filed: October 18, 2019
    Date of Patent: March 1, 2022
    Assignee: ACCELERON PHARMA INC.
    Inventor: Kenneth M. Attie
  • Patent number: 11253829
    Abstract: Process for the production of solid particles comprising a material with melting point from ?20 to 300° C. at atmospheric pressure, characterized in that a mixture comprising: a1) the material in molten form and a2) the material in solid form is mixed by means of an extruder to give a paste, this is forced through a pelletizing die to give strands, and the strands are comminuted.
    Type: Grant
    Filed: November 29, 2016
    Date of Patent: February 22, 2022
    Assignee: LANXESS Deutschland GmbH
    Inventors: Michael Witt, Nikolaj Caspers, Ulrich-Peter Szczecina
  • Patent number: 11253602
    Abstract: The present invention provides dendrimer conjugates. The present invention provides a composition comprising a dendrimer conjugate and a cell, such as a cell covered with dendrimer conjugates, in which dendrimer conjugates home the cell to a target tissue.
    Type: Grant
    Filed: September 11, 2019
    Date of Patent: February 22, 2022
    Assignee: UNIVERSITY OF MIAMI
    Inventors: Omaida Velazquez, Sylvia Daunert, Pirouz Daftarian, Zhao-Jun Liu, Sapna Deo
  • Patent number: 11253578
    Abstract: Compositions include highly-concentrated Alpha-1 Proteinase Inhibitor (A1PI) in a concentration greater than or equal to 100 mg/ml. Pharmaceutical compositions can be prepared from these compositions. The pharmaceutical compositions can be suitable for subcutaneous administration. The highly-concentrated A1PI solutions can be obtained by single-pass tangential flow filtration (SPTFF).
    Type: Grant
    Filed: August 1, 2019
    Date of Patent: February 22, 2022
    Assignee: GRIFOLS WORLDWIDE OPERATIONS LIMITED
    Inventors: James Rebbeor, Charles Miller, Anthony Klos, Eric Allgaier, Thomas P. Zimmerman, Kevin Wee, Michelle StPeter, Kelly Glancy
  • Patent number: RE49026
    Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.
    Type: Grant
    Filed: October 6, 2017
    Date of Patent: April 12, 2022
    Assignee: MEDICAL DIAGNOSTIC LABORATORIES, LLC
    Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis